Abstract
Urinary tract infection (UTI) is a relevant public health problem, economically and socially affecting the lives of patients. The increase of antimicrobial bacterial resistance significantly hinders the treatment of UTIs, raising the need to search for alternative therapies. Bacterial lysates (BL) obtained from Escherichia coli and other pathogens have been used to treat different infectious diseases with promising results. This work aims to evaluate the effect and composition of an autologous BL for the treatment and control of recurrent UTIs in adults. The results show remission in 70% of the patients within the first three months after the administration of BL, while the infection is maintained under control for 6–12 months. The analysis by liquid chromatography–mass spectrometry (LC-MS) of the BL fractions recognized by the sera of patients shows the presence of cytosolic proteins, fimbriae, OMPs, and LPS. Our study demonstrates that the autologous BL contributed to the treatment and control of recurrent UTIs in adults, and its composition shows that different surface components of E. coli are potential immunogens that could be used to create a polyvalent protective vaccine.
Highlights
Urinary tract infection (UTIs) is an important health concern worldwide, with over 150 million cases reported every year [1]
Aimed at the prevention and control of recurrent UTIs, SolcoUrovac, OM-89/Urovaxom, and most recently Uromune®, are bacterial immunostimulants manufactured with a mixture of whole bacterial lysates (BL) from several uropathogen strains that have shown variation in their efficacy [4,9,10]
13 patients remained for the completion of the one-year follow-up, while some patients stayed for 33 months (Table S1)
Summary
Urinary tract infection (UTIs) is an important health concern worldwide, with over 150 million cases reported every year [1]. Antibiotics are the most commonly prescribed therapy to treat UTIs; multidrug-resistant (MDR) UPEC strains have recently emerged, hampering the treatment and control of these infections [4,5]. Pathogens 2020, 9, 102 the WHO has included E. coli in a list of pathogens for special consideration due to their MDR profile and the difficulty this poses for the treatment and control of the illnesses these bacteria give rise to. It has encouraged the development of alternative therapies for the treatment of these diseases [6]. The immunogenic components of the BL from the four most prevalent E. coli serogroups were identified, gaining insight that will contribute to the development of a vaccine (polyvalent immunogenic stimulant) to treat and control UTIs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
